AstraZeneca's Etcamah Misses Primary PFS Endpoint in Phase III SERENA-4 First-Line Breast Cancer Trial
核心洞察
AstraZeneca's Phase III SERENA-4 trial of camizestrant (Etcamah) plus palbociclib failed to meet its primary progression-free survival endpoint in ER-positive, HER2-negative advanced breast cancer (搜索).
A numerical PFS improvement was observed versus anastrozole plus palbociclib, but the difference did not reach statistical significance, with detailed results pending future presentation.
The safety profile of the combination was consistent with the known profiles of each medicine, and no new safety concerns were identified.
AstraZeneca's Phase III SERENA-4 trial evaluating camizestrant (branded Etcamah) in combination with palbociclib did not meet its primary endpoint of a statistically significant improvement in progression-free survival (PFS) in the upfront first-line treatment of patients with estrogen receptor (搜索) (ER)-positive, HER2-negative advanced breast cancer, the company announced on Friday.
A numerical improvement in PFS was observed with camizestrant plus palbociclib compared with anastrozole plus palbociclib, but the difference did not reach statistical significance. Detailed efficacy results, including the magnitude of the PFS difference, have not yet been disclosed and are expected to be presented at a later date. U.S.-listed shares of AstraZeneca fell 3% in aftermarket trading following the disclosure.
Trial Design and Patient Population
SERENA-4 (NCT04711252) is a global, randomized, multicenter, double-blind Phase III trial comparing camizestrant plus palbociclib with anastrozole plus palbociclib as initial systemic treatment for ER-positive, HER2-negative advanced breast cancer (搜索). Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor.
The study enrolled 1,371 adults with newly diagnosed Stage IV de novo or recurrent advanced disease who had not previously received systemic therapy for advanced breast cancer. For patients whose disease recurred after early-stage breast cancer, eligibility required at least 24 months of prior standard adjuvant endocrine therapy and an appropriate treatment-free interval following aromatase inhibitor therapy.
The primary endpoint was investigator-assessed PFS. Secondary endpoints include overall survival, second progression-free survival and health-related quality of life.
Safety Findings
According to the company, the safety profile of camizestrant in combination with palbociclib was consistent with the known profiles of each medicine, with no new safety concerns identified.
SERENA-4 Versus SERENA-6: Distinct Treatment Strategies
The negative primary endpoint in SERENA-4 is distinct from the positive findings of the SERENA-6 Phase III trial, which established the clinical benefit of camizestrant in a biomarker-selected first-line setting. SERENA-4 investigated whether replacing an aromatase inhibitor with camizestrant from the beginning of first-line treatment, in combination with palbociclib, could improve outcomes in a broad ER-positive, HER2-negative advanced breast cancer (搜索) population.
SERENA-6, by contrast, used circulating tumor DNA monitoring to identify patients who developed an ESR1 (搜索) mutation while receiving first-line aromatase inhibitor plus CDK4/6 (搜索) inhibitor therapy but before radiographic disease progression. Those patients were then randomized to switch endocrine therapy to camizestrant while continuing their CDK4/6 inhibitor or to remain on their aromatase inhibitor-based regimen.
In the initial SERENA-6 analysis, median PFS was 16.0 months with camizestrant versus 9.2 months with continued aromatase inhibitor therapy, corresponding to a hazard ratio for progression or death of 0.44. With longer follow-up, median PFS was reported at 16.8 versus 9.2 months, respectively, while the benefit extended to second progression-free survival.
Regulatory Context
The SERENA-4 announcement comes only one week after the U.S. Food and Drug Administration granted accelerated approval to camizestrant (Etcamah) in combination with a CDK4/6 (搜索) inhibitor — abemaciclib, palbociclib or ribociclib — for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer following detection of an ESR1 (搜索) mutation during aromatase inhibitor and CDK4/6 inhibitor treatment. The approval, announced on September 4, 2026, was based on the SERENA-6 results. The FDA also approved Guardant360 CDx (搜索) as a companion diagnostic for identifying eligible patients with ESR1 mutations. Camizestrant is also cleared in the European Union for this form of breast cancer.
The different outcomes of SERENA-4 and SERENA-6 highlight an important distinction in the development of camizestrant: while replacing an aromatase inhibitor with camizestrant universally at the start of first-line therapy did not produce a statistically significant PFS advantage in SERENA-4, biomarker-guided switching after the emergence of an ESR1 (搜索) mutation has demonstrated significant clinical benefit.
Mechanism and Resistance Biology
Camizestrant is a next-generation oral selective estrogen receptor (搜索) degrader (SERD) and complete estrogen receptor antagonist designed to inhibit ER-driven tumor growth. ESR1 (搜索) mutations are an important mechanism of acquired resistance to endocrine therapy in HR-positive breast cancer. They can emerge during aromatase inhibitor treatment and may be detected in circulating tumor DNA before conventional clinical or radiological disease progression.
Company Perspective and Ongoing Development
Susan Galbraith, Executive Vice President, Oncology Haematology R&D at AstraZeneca, commented on the result: "Whilst we are disappointed by the SERENA-4 outcome, it sharpens our focus on maximising the number of patients who can benefit from Etcamah today based on SERENA-6 and reinforces the importance of ESR1 (搜索) testing for patients on first-line therapy."
Galbraith added that early breast cancer represents an important opportunity, and the company remains confident in the long-term potential of the drug.
Despite the SERENA-4 result, AstraZeneca is continuing the development of camizestrant in early-stage breast cancer. The Phase III CAMBRIA-1 and CAMBRIA-2 trials are evaluating camizestrant across adjuvant treatment settings in patients at intermediate or high risk of recurrence. Together, the company's early breast cancer camizestrant program involves approximately 10,000 patients and includes evaluation of the drug as monotherapy, in combination with CDK4/6 (搜索) inhibitors and following CDK4/6 inhibitor therapy.
The SERENA-4 result does not affect Etcamah's currently approved use in patients with ESR1 (搜索)-mutated disease, which is based on findings from the SERENA-6 program. AstraZeneca said the trial data will be shared in due course.
Commercial Outlook
AstraZeneca sees the pill as a potential blockbuster, projecting more than $5 billion in yearly sales. Analysts surveyed by Bloomberg expect about $2 billion in 2031 revenue, and Bloomberg Intelligence's Tonia Kefala Stavridi and John Murphy estimate that success in this first-line setting could unlock nearly $2 billion more.
Full results from SERENA-4 will be important for understanding the extent of the numerical PFS difference, outcomes across clinically relevant patient subgroups and the implications of the findings for the broader development of oral SERDs in first-line advanced breast cancer.